Dual Antiplatelet Treatment up to 72 Hours after Ischemic Stroke
Authors:
- Ying GaoYGYing Gao
- Weiqi ChenWCWeiqi Chen
- Yuesong PanYPYuesong Pan
- Jing JingJJJing Jing
- Chunjuan WangCWChunjuan Wang
- S. Claiborne JohnstonSJS. Claiborne Johnston
- Pierre AmarencoPAPierre Amarenco
- Philip M. BathPBPhilip M. Bath
- Lingling JiangLJLingling Jiang
- Yingying YangYYYingying Yang
- Tingting WangTWTingting Wang
- Shangrong HanSHShangrong Han
Top Cited Papers
- 28 December 2023
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 389 (26) , 2413-2424
Abstract
Dual antiplatelet treatment has been shown to lower the risk of recurrent stroke as compared with aspirin alone when treatment is initiated early (≤24 hours) after an acute mild stroke. The effect of clopidogrel plus aspirin as compared with aspirin alone administered within 72 hours after the onset of acute cerebral ischemia from atherosclerosis has not been well studied. In 222 hospitals in China, we conducted a double-blind, randomized, placebo-controlled, two-by-two factorial trial involving patients with mild ischemic stroke or high-risk transient ischemic attack (TIA) of presumed atherosclerotic cause who had not undergone thrombolysis or thrombectomy. Patients were randomly assigned, in a 1:1 ratio, within 72 hours after symptom onset to receive clopidogrel (300 mg on day 1 and 75 mg daily on days 2 to 90) plus aspirin (100 to 300 mg on day 1 and 100 mg daily on days 2 to 21) or matching clopidogrel placebo plus aspirin (100 to 300 mg on day 1 and 100 mg daily on days 2 to 90). There was no interaction between this component of the factorial trial design and a second part that compared immediate with delayed statin treatment (not reported here). The primary efficacy outcome was new stroke, and the primary safety outcome was moderate-to-severe bleeding - both assessed within 90 days. A total of 6100 patients were enrolled, with 3050 assigned to each trial group. TIA was the qualifying event for enrollment in 13.1% of the patients. A total of 12.8% of the patients were assigned to a treatment group no more than 24 hours after stroke onset, and 87.2% were assigned after 24 hours and no more than 72 hours after stroke onset. A new stroke occurred in 222 patients (7.3%) in the clopidogrel-aspirin group and in 279 (9.2%) in the aspirin group (hazard ratio, 0.79; 95% confidence interval [CI], 0.66 to 0.94; P = 0.008). Moderate-to-severe bleeding occurred in 27 patients (0.9%) in the clopidogrel-aspirin group and in 13 (0.4%) in the aspirin group (hazard ratio, 2.08; 95% CI, 1.07 to 4.04; P = 0.03). Among patients with mild ischemic stroke or high-risk TIA of presumed atherosclerotic cause, combined clopidogrel-aspirin therapy initiated within 72 hours after stroke onset led to a lower risk of new stroke at 90 days than aspirin therapy alone but was associated with a low but higher risk of moderate-to-severe bleeding. (Funded by the National Natural Science Foundation of China and others; INSPIRES ClinicalTrials.gov number, NCT03635749.).Keywords
Funding Information
- ‘National Ten-Thousand Talent Plan’- Leadership of Scientific and Technological Innovation
- Sanofi
- Jialin Pharmaceutical
- China National Funds for Distinguished Young Scientists (81825007)
- National Key Research and Development Program of China (2017YFC1307900, 2017YFC1307905)
- Beijing Outstanding Young Scientist Program (BJJWZYJH01201910025030)
- Youth Beijing Scholar Program (010)
- Beijing Young Top- notch Talent Project (2018A12)
This publication has 26 references indexed in Scilit:
- Efficacy and safety of ticagrelor versus aspirin in acute stroke or transient ischaemic attack of atherosclerotic origin: a subgroup analysis of SOCRATES, a randomised, double-blind, controlled trialThe Lancet Neurology, 2017
- One-Year Risk of Stroke after Transient Ischemic Attack or Minor StrokeNew England Journal of Medicine, 2016
- Factors Associated With Recurrent Ischemic Stroke in the Medical Group of the SAMMPRIS TrialJAMA Neurology, 2016
- Dual antiplatelet therapy in stroke and ICASNeurology, 2015
- Early Dual Versus Mono Antiplatelet Therapy for Acute Non-Cardioembolic Ischemic Stroke or Transient Ischemic AttackCirculation, 2013
- Clopidogrel with Aspirin in Acute Minor Stroke or Transient Ischemic AttackNew England Journal of Medicine, 2013
- Stenting versus Aggressive Medical Therapy for Intracranial Arterial StenosisNew England Journal of Medicine, 2011
- Cytochrome P-450 Polymorphisms and Response to ClopidogrelNew England Journal of Medicine, 2009
- Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trialThe Lancet, 2006
- An International Randomized Trial Comparing Four Thrombolytic Strategies for Acute Myocardial InfarctionNew England Journal of Medicine, 1993